Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02491099 · ClinicalTrials.gov registry record · Phase 2
A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma
A Phase 2 study of HER2/Neu+ Uterine Serous Carcinoma, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT02491099 is a Phase 2 study of HER2/Neu+ Uterine Serous Carcinoma that is actively recruiting participants, run by Yale University. The registered enrollment target is 50 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT02491099, a Phase 2 study of HER2/Neu+ Uterine Serous Carcinoma, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
Primary Objective: To assess the activity of Afatinib in patients with persistent or recurrent uterine serous carcinoma overexpressing HER2/neu with the frequency of patients who survive progression-free for at least 6 months after initiating therapy. Secondary Objectives: To assess objective response rate and durable disease control rate. To assess overall survival. To assess the safety profile of Afatinib in uterine serous carcinoma patients.
Conditions Studied
Interventions
- DRUG Afatinib
Study Locations (3)
Arizona
- University of Arizona Cancer Center - Tucson
Connecticut
- Yale New Haven Hospital - New Haven
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2015-06 |
| Est. Completion | 2028-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02491099
The ClinicalTrials.gov registry entry for NCT02491099 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HER2/Neu+ Uterine Serous Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Afatinib is the first listed.
NCT02491099 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Connecticut, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02491099 about?
NCT02491099 is a clinical study titled "A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma". Primary Objective: To assess the activity of Afatinib in patients with persistent or recurrent uterine serous carcinoma overexpressing HER2/neu with the frequency of patients who survive progression-free for at least 6 months after initiating therapy. Secondary Objectives: To assess objective respon...
What is the current status of trial NCT02491099?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2015-06. Estimated completion is 2028-07.
What conditions does trial NCT02491099 study?
This clinical trial studies the following conditions: HER2/Neu+ Uterine Serous Carcinoma.
What interventions are being tested in trial NCT02491099?
The interventions under investigation include: Afatinib (DRUG).
Who is sponsoring clinical trial NCT02491099?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02491099 being conducted?
This trial has 3 study locations across Arizona, Connecticut, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.